BD's Revello™ Stent Receives CE Mark, Enhancing Treatment for Peripheral Artery Disease
- Becton Dickinson's Revello™ Stent received CE Marking, improving treatment for peripheral artery disease in the European Union.
- The stent features an advanced design that protects healthy tissue and enhances procedural safety during deployment.
- BD's commitment includes expanding its vascular portfolio and providing training for healthcare professionals using the new technology.
BD Advances Vascular Treatment with CE Mark for Revello™ Stent
Becton, Dickinson and Company (BD) recently announces that its Revello™ Vascular Covered Stent has received CE Marking, marking a significant breakthrough in the treatment of atherosclerotic lesions in the common and external iliac arteries. This development arrives at a critical time when lower-limb peripheral artery disease (PAD), especially prevalent among the aging population in the European Union, presents major health challenges. The Revello™ Stent's self-expanding design, featuring an ultrathin expanded polytetrafluoroethylene covering, plays a pivotal role in maintaining the patency of the iliac arteries while accommodating their anatomical nuances. The stent aims to enhance patient outcomes by incorporating features that protect adjacent healthy tissue during placement and deployment.
The Revello™ Stent integrates advanced technology to ensure precision and safety during procedures. For instance, the stent's compliant ends are designed to minimize trauma to surrounding healthy vessels, while tantalum radiopaque markers facilitate enhanced visualization during fluoroscopy. Such details are critical when navigating complex anatomical variations. BD emphasizes that the introduction of this next-generation stent could revolutionize how physicians address complex iliac artery conditions, thereby potentially improving quality of care for patients with PAD across Europe and the European Economic Area (EEA).
Rima Alameddine, Worldwide President of BD Interventional - Peripheral Intervention, underscores the importance of this CE Marking as a substantial milestone in BD's commitment to combating peripheral artery disease. Along with the innovative features of the Revello™ Stent, the company has developed a tri-axial delivery system intended to enhance control during deployment, ensuring precise stent positioning. With various sizes available, the Revello™ Stent is designed to meet diverse patient needs, allowing healthcare providers to offer improved treatment options for a condition that affects a significant portion of the growing aging demographic.
In addition to the Revello™ Stent's promising features, BD's engagement in expanding its peripheral vascular product portfolio showcases its strategic focus on addressing complex clinical challenges in vascular health. This development not only reflects BD's innovation-driven approach but also signals a proactive response to the increasing burden of PAD, representing a potential shift in treatment paradigms for this chronic condition.
Furthermore, BD’s ongoing commitment to patient outcomes is evident through the comprehensive training and resources provided to healthcare professionals for the effective use of this new stenting technology. As healthcare needs evolve, BD continues to position itself at the forefront of medical technology, addressing not only immediate patient requirements but also the broader implications for cardiovascular health management.